Halliburton Labs has added three energy tech startups to its program. Photo via Getty Images

Halliburton Labs has announced its latest cohort — and revealed details about its next pitch day.

The program, housed at Halliburton's facilities in Houston, added FuelX, LiNa Energy, and Solaires Entreprises to the clean energy accelerator. The companies will receive support from mentors from within Halliburton's workforce and network, as well as go through the accelerator's programming.

“We’re excited to support FuelX, LiNa Energy, and Solaires with the tools they need to achieve their goals,” says Halliburton Labs Managing Director Dale Winger in a news release. “Each participant company receives customized support to enable efficient use of their time and capital by engaging Halliburton’s scaling experience and capabilities.”

The next Halliburton Labs will not take place in Houston. The program is going on the road to host its next Halliburton Labs Finalists Pitch Day on Thursday, September 21, in Denver. The event will be a part of the inaugural Energy Tech Day at Denver Startup Week and will include pitches from innovative, early-stage energy tech companies.

FuelX

FuelX, which has a production plant in the Houston area, manufactures hydrogen storage materials and fuel cell power systems with alane solid state hydrogen fuel.

“Participation in the Halliburton Labs program accelerates our ability to scale to meet existing military and commercial project milestones,” says Greg Jarvie, co-founder and CEO of FuelX.

LiNa Energy

Headquartered in Lancaster, England, LiNa Energy develops and provides low-cost, solid-state sodium batteries.

"LiNa is delighted to be selected for Halliburton Labs – the support and investment will accelerate LiNa's growth on a scale found only in the energy industry,” says Chief Commercial Officer Will Tope. “Halliburton Labs is a cornerstone of our strategy, as we scale up manufacturing to deliver bigger energy storage systems to our partners around the world."

Solaires Entreprises

Solaires Entreprises, based in Victoria, British Columbia, is developing lightweight, flexible, efficient, and transparent solar cells.

“Our company is purpose-driven toward what our technology can achieve: a more affordable and reliable alternative within solar energy and photovoltaics and where renewables become a bigger portion of the world power mix,” says Solaires Co-founder and Chief Science Officer Sahar Sam.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Intel Corp. and Rice University sign research access agreement

innovation access

Rice University’s Office of Technology Transfer has signed a subscription agreement with California-based Intel Corp., giving the global company access to Rice’s research portfolio and the opportunity to license select patented innovations.

“By partnering with Intel, we are creating opportunities for our research to make a tangible impact in the technology sector,” Patricia Stepp, assistant vice president for technology transfer, said in a news release.

Intel will pay Rice an annual subscription fee to secure the option to evaluate specified Rice-patented technologies, according to the agreement. If Intel chooses to exercise its option rights, it can obtain a license for each selected technology at a fee.

Rice has been a hub for innovation and technology with initiatives like the Rice Biotech Launch Pad, an accelerator focused on expediting the translation of the university’s health and medical technology; RBL LLC, a biotech venture studio in the Texas Medical Center’s Helix Park dedicated to commercializing lifesaving medical technologies from the Launch Pad; and Rice Nexus, an AI-focused "innovation factory" at the Ion.

The university has also inked partnerships with other tech giants in recent months. Rice's OpenStax, a provider of affordable instructional technologies and one of the world’s largest publishers of open educational resources, partnered with Microsoft this summer. Google Public Sector has also teamed up with Rice to launch the Rice AI Venture Accelerator, or RAVA.

“This agreement exemplifies Rice University’s dedication to fostering innovation and accelerating the commercialization of groundbreaking research,” Stepp added in the news release.

Houston team develops low-cost device to treat infants with life-threatening birth defect

infant innovation

A team of engineers and pediatric surgeons led by Rice University’s Rice360 Institute for Global Health Technologies has developed a cost-effective treatment for infants born with gastroschisis, a congenital condition in which intestines and other organs are developed outside of the body.

The condition can be life-threatening in economically disadvantaged regions without access to equipment.

The Rice-developed device, known as SimpleSilo, is “simple, low-cost and locally manufacturable,” according to the university. It consists of a saline bag, oxygen tubing and a commercially available heat sealer, while mimicking the function of commercial silo bags, which are used in high-income countries to protect exposed organs and gently return them into the abdominal cavity gradually.

Generally, a single-use bag can cost between $200 and $300. The alternatives that exist lack structure and require surgical sewing. This is where the SimpleSilo comes in.

“We focused on keeping the design as simple and functional as possible, while still being affordable,” Vanshika Jhonsa said in a news release. “Our hope is that health care providers around the world can adapt the SimpleSilo to their local supplies and specific needs.”

The study was published in the Journal of Pediatric Surgery, and Jhonsa, its first author, also won the 2023 American Pediatric Surgical Association Innovation Award for the project. She is a recent Rice alumna and is currently a medical student at UTHealth Houston.

Bindi Naik-Mathuria, a pediatric surgeon at UTMB Health, served as the corresponding author of the study. Rice undergraduates Shreya Jindal and Shriya Shah, along with Mary Seifu Tirfie, a current Rice360 Global Health Fellow, also worked on the project.

In laboratory tests, the device demonstrated a fluid leakage rate of just 0.02 milliliters per hour, which is comparable to commercial silo bags, and it withstood repeated disinfection while maintaining its structure. In a simulated in vitro test using cow intestines and a mock abdominal wall, SimpleSilo achieved a 50 percent reduction of the intestines into the simulated cavity over three days, also matching the performance of commercial silo bags. The team plans to conduct a formal clinical trial in East Africa.

“Gastroschisis has one of the biggest survival gaps from high-resource settings to low-resource settings, but it doesn’t have to be this way,” Meaghan Bond, lecturer and senior design engineer at Rice360, added in the news release. “We believe the SimpleSilo can help close the survival gap by making treatment accessible and affordable, even in resource-limited settings.”